<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2012-10-09 13:17:59Pharmaceutical sciences Clinical research Corporate crime Dow Jones Industrial Average Valdecoxib Qui tam Office of Criminal Investigations Off-label use Office of Inspector General U.S. Department of Health and Human Services Law Pfizer Pharmacology |
| breyer celebrex, fda celebrex news celebrex class action rasansky celebrex attorney dallas celebrex rash arthritis with celebrex, celebrex and liver damage new york celebrex attorney. taking expired celebrexDocID: 1fCfD - View Document |
| PDF DocumentDocID: 16iWT - View Document |
| The Need for Revision of Pre-Market Testing The Failure of Animal Tests of COX-2 Inhibitors John J. Pippin, M.D., F.A.C.C. FDA Open Public Hearing Arthritis Advisory CommitteeDocID: 13ofP - View Document |
| April 27, 2010 Pfizer, Inc. 235 East 42nd Street New York, NY[removed]ATTN: Public Relations or Press Office Dear Sir or Madam:DocID: NDut - View Document |
| DEPARTMENT OF HEALTH & HUMAN SERVICES MEMORANDUM Public Health ServiceDocID: D1qI - View Document |